Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...

The short answer is no, you cannot outgrow asthma, but your symptoms may be less severe. Learn when asthma goes into ...

Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Allakos (ALLK) announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria. In the CSU cohort, 34 adult ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

This is just a sampling of medical advancements in 2024 chosen for their common presence in the American population. It is ...

Investing.com -- Shares of Allakos Inc . (NASDAQ: ALLK) plummeted 76% after the biopharmaceutical company announced the discontinuation of its AK006 development due to the drug's lack of therapeutic ...

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low ...

RPT904 is designed to provide a potential alternative to omalizumab (Xolair), addressing allergic conditions such as asthma and chronic spontaneous urticaria SOUTH SAN FRANCISCO, Calif., ...